Iovance Biotherapeutics

IOVA · Nasdaq · United States

Share price · IOVA

$7.48+0.45 (+6.40%) 3M

close as of 2026-11-18 · 24h delayed · vol 7.0M (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IOVA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 29 Oct 2026-35.4%
  2. 29 Sep 2026+31.5%
  3. 20 Aug 2026+12.5%
  4. 6 Aug 2026+43.1%
  5. 31 Jul 2026-13.2%
  6. 15 Jul 2026+20.6%
  7. 4 Jun 2026+15.6%
  8. 22 May 2026+11.1%
  9. 9 Apr 2026+15.6%
  10. 12 Mar 2026-15.9%

    Nothing announced by IOVA that day or the session before.

Share of unusual movement by asset

For each asset, the share of IOVA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(5 total)
5Total Assets
2Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
aldesleukin(Proleukin)
Approved
Interleukin-2 receptor (IL-2R)Other
Renal Cell CarcinomaMelanoma
lifileucel(Amtagvi)
Approved
Tumor-infiltrating lymphocytes (polyclonal tumor antigens)Cell therapy
Melanoma
Phase 2
No discrete molecular targetCell therapy
Non-Small Cell Lung Cancer
Phase 2
Tumor-infiltrating lymphocytes (TIL)
Non-Small Cell Lung Cancer
Phase 1/2
PD-1Cell therapy
Non-Small Cell Lung Cancer

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (1)
IOV-4001Phase 1/2Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Est. primary completion 2027-09 · NCT05361174 · CT.gov ↗
What to watch
December 2027 (1)
lifileucel · AmtagviPhase 2Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
Est. primary completion 2027-12 · NCT07288203 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
lifileucel · AmtagviPhase 3Metastatic Melanoma, Unresectable Melanoma, Melanoma
Est. primary completion 2028-03-01 · NCT05727904 · CT.gov ↗
What to watch
May 2028 (1)
lifileucel · AmtagviPhase 2Endometrial Cancer
Est. primary completion 2028-05 · NCT06481592 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
LN-145Phase 2Metastatic Non Small Cell Lung Cancer
Est. primary completion 2030-12 · NCT04614103 · CT.gov ↗
What to watch
2032 (1)
June 2032 (1)
lifileucel · AmtagviPhase 1/2Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Est. primary completion 2032-06 · NCT06940739 · CT.gov ↗
What to watch
2033 (1)
September 2033 (1)
lifileucel · AmtagviPhase 2Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) …
Est. primary completion 2033-09-01 · NCT07741877 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 June 2026ApprovallifileucelAmtagvi approved in Australia for advanced melanoma
AU, TGA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$121M$49M$64M+ $318M short-term inv.$22M-$4.5M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$99M$59M$117M+ $187M short-term inv.$47M-$61M operating cash flowreport ↗
2026-Q1$71M$62M$197M+ $117M short-term inv.$79M-$72M operating cash flowreport ↗
2025-Q3$67M$75M$164M+ $143M short-term inv.$91M-$79M operating cash flowreport ↗
2025-Q2$60M$79M$138M+ $169M short-term inv.$112M-$67M operating cash flowreport ↗
2025-Q1$49M$77M$178M+ $188M short-term inv.$116M-$104M operating cash flowreport ↗
2024-Q3$59M$68M$171M+ $233M short-term inv.$84M-$59M operating cash flowreport ↗
2024-Q2$31M$62M$235M+ $184M short-term inv.$97M-$98M operating cash flowreport ↗
2024-Q1$0.7M$80M$141M+ $222M short-term inv.$113M-$122M operating cash flowreport ↗
2023-Q3$0.5M$88M$334M+ $94M short-term inv.$114M-$84M operating cash flowreport ↗
2023-Q2$0.2M$86M$296M+ $21M short-term inv.$107M-$94M operating cash flowreport ↗
2023-Q1—$83M$550M+ $83M short-term inv.$107M-$100M operating cash flowreport ↗
2022-Q3—$73M$125M+ $242M short-term inv.$100M-$64M operating cash flowreport ↗
2022-Q2—$73M$115M+ $316M short-term inv.$99M-$78M operating cash flowreport ↗
2022-Q1—$68M$98M+ $390M short-term inv.$92M-$74M operating cash flowreport ↗
2021-Q3—$65M$65M+ $518M short-term inv.$86M-$58M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$264M$300M$163M+ $134M short-term inv.$98M-$302M operating cash flowreport ↗

Iovance reported full-year 2025 revenue of $263.502M, up 60.6% YoY, and R&D spend of $300.27M, up 8.7% YoY. The company ended the year with a cash position of approximately $303M and reported a net loss of $390.978M.

The company achieved its FY25 revenue guidance of $250–300M and expects its cash position to fund operations into the third quarter of 2027. Key business updates included FDA Fast Track designation for lifileucel in second-line advanced non-small cell lung cancer, positive interim data in that setting, and a planned registrational trial in previously treated advanced sarcomas. Amtagvi's five-year C-144-01 analysis and real-world response data, along with ongoing global regulatory submissions, were also highlighted.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$164M$276M$116M+ $208M short-term inv.$93M-$353M operating cash flowreport ↗
2023-FY$1.2M$333M$115M+ $165M short-term inv.$111M-$362M operating cash flowreport ↗
2022-FY—$295M$238M+ $240M short-term inv.$99M-$293M operating cash flowreport ↗
2021-FY—$259M$84M+ $426M short-term inv.$86M-$228M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-11Vogt Frederick G · director, Interim CEO & General CounselOption exercise200,000$7.55$1.5MForm 4
2026-11-11Vogt Frederick G · director, Interim CEO & General CounselTax withholding191,303$8.09$1.5MForm 4
2026-11-11Vogt Frederick G · director, Interim CEO & General CounselOption exercise (derivative)200,000——Form 4
2026-11-10Kirby Daniel Gordon · Chief Commercial OfficerOption exercise10,000——Form 4
2026-11-10Kirby Daniel Gordon · Chief Commercial OfficerTax withholding3,935$8.08$32KForm 4
2026-11-10Kirby Daniel Gordon · Chief Commercial OfficerOption exercise (derivative)10,000——Form 4
2026-11-06Roche Corleen M. · Chief Financial OfficerOption exercise12,500——Form 4
2026-11-06Roche Corleen M. · Chief Financial OfficerTax withholding5,311$8.04$43KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 283 reporting institutions held 269.0M shares ($910.0M, 58.1% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.31,080,505$109.1M
2MHR FUND MANAGEMENT LLC28,967,103$101.7M
3STATE STREET CORP17,448,108$61.2M
4VANGUARD CAPITAL MANAGEMENT LLC16,617,737$58.3M
5TWO SIGMA INVESTMENTS, LP13,687,433$48.0M
6VANGUARD PORTFOLIO MANAGEMENT LLC11,700,844$41.1M
7MILLENNIUM MANAGEMENT LLC9,414,292$33.0M
8GOLDMAN SACHS GROUP INC8,760,060$30.7M
9GEODE CAPITAL MANAGEMENT, LLC8,572,598$30.1M
10Invenomic Capital Management LP8,495,551$29.8M
11BANK OF AMERICA CORP /DE/8,490,119$29.8M
12D. E. Shaw & Co., Inc.8,016,353$28.1M
13Palo Alto Investors LP6,349,563$22.3M
14MORGAN STANLEY6,201,282$21.8M
15JANE STREET GROUP, LLC4,173,886$14.7M